David Boyer Biography and Net Worth

David W. Boyer was appointed Chief Corporate Affairs Officer in September 2019 and is responsible for patient advocacy and engagement, corporate communications, government relations, and public policy at Neurocrine Biosciences. Mr. Boyer brings nearly 20 years of experience in public affairs, specializing in the life sciences and biopharmaceutical sectors. He joins Neurocrine Biosciences after nine years with the BGR Group, where he served as a Principal and the Head of the Health & Lifesciences Practice, leading the firm’s healthcare advocacy, policy and strategy development, and strategic consulting team. During his tenure at the BGR Group, Mr. Boyer led public policy, advocacy, and strategic communications initiatives for a wide range of healthcare clients. Prior to joining the BGR Group, Mr. Boyer served as Special Assistant to the President for Legislative Affairs under President George W. Bush, Assistant Commissioner for Legislation at the U.S. Food and Drug Administration, and Special Assistant to the Secretary at the U.S. Department of Health and Human Services. In addition to his public service, Mr. Boyer held senior advocacy positions at the Biotechnology Innovation Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Boyer holds a B.A. in Government from Georgetown University.

What is David W. Boyer's net worth?: The estimated net worth of David W. Boyer is at least $665,535.06 as of February 6th, 2024. Mr. Boyer owns 4,894 shares of Neurocrine Biosciences stock worth more than $665,535 as of April 26th. This net worth evaluation does not reflect any other assets that Mr. Boyer may own. Learn More about David W. Boyer's net worth.
How old is David W. Boyer?: Mr. Boyer is currently 44 years old. There are 8 older executives and no younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who is 66 years old. Learn More on David W. Boyer's age.
How do I contact David W. Boyer?: The corporate mailing address for Mr. Boyer and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on David W. Boyer's contact information.
Has David W. Boyer been buying or selling shares of Neurocrine Biosciences?: David W. Boyer has not been actively trading shares of Neurocrine Biosciences during the last quarter. Most recently, David W. Boyer sold 1,328 shares of the business's stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $135.41, for a transaction totalling $179,824.48. Following the completion of the sale, the insider now directly owns 4,895 shares of the company's stock, valued at $662,831.95. Learn More on David W. Boyer's trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 45 times. They sold a total of 498,958 shares worth more than $65,104,745.00. The most recent insider tranaction occured on April, 15th when insider Eric Benevich sold 19,818 shares worth more than $2,642,928.48. Insiders at Neurocrine Biosciences own 4.4% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 4/15/2024.

David W. Boyer Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/8/2024	Sell	1,328	$135.41	$179,824.48	4,895
2/6/2024	Sell	456	$141.96	$64,733.76	4,894
10/2/2023	Sell	1,437	$112.68	$161,921.16	4,894
8/30/2023	Sell	2,733	$107.60	$294,070.80	3,460
10/3/2022	Sell	1,437	$106.59	$153,169.83	4,214
2/7/2022	Sell	240	$81.07	$19,456.80

David W. Boyer Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $135.99

$135.17

$138.61

50 Day Range

MA: $136.63

$130.40

$143.74

2 Week Range

Now: $135.99

$89.04

$148.37

Volume

717,575 shs

Average Volume

847,914 shs

Market Capitalization

$13.53 billion

P/E Ratio

56.19

Dividend Yield

N/A

Beta

0.25

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

David Boyer Biography and Net Worth

What is David W. Boyer's net worth?

How old is David W. Boyer?

How do I contact David W. Boyer?

Has David W. Boyer been buying or selling shares of Neurocrine Biosciences?

Who are Neurocrine Biosciences' active insiders?

Are insiders buying or selling shares of Neurocrine Biosciences?